InvestorsHub Logo
Followers 6
Posts 1087
Boards Moderated 0
Alias Born 07/18/2006

Re: None

Monday, 07/16/2018 8:51:55 AM

Monday, July 16, 2018 8:51:55 AM

Post# of 17420
"Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in the First Half of 2018"

excerpt:
"Aurinia recently initiated a dry-eye study that will randomize around 90 patients into groups receiving voclosporin or Restasis from Allergan (NYSE:AGN). If voclosporin can best the market leader, this stock could soar further in the second half than it did in the first. Dosing has already begun, and patients will be evaluated after four weeks, so keep an eye open for the hotly anticipated results."


https://www.fool.com/investing/2018/07/14/heres-why-aurinia-pharmaceuticals-inc-gained-322-i.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News